- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
International Hepatitis Expert from CDC to Manage R&D and Collaborations
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that Howard Fields, PhD, currently a member of the Scientific Advisory Board, will join the Company as Vice President of Virology.
"We're very pleased to have Dr. Fields, a scientist of great international repute, joining us. He will guide, manage, and coordinate our extensive activities in all aspects of virology. His international experience in developing novel approaches to problems in virology, and in successfully managing multi-national collaborations amongst various agencies, will be of tremendous benefit to NanoViricides," said Eugene Seymour, MD, MPH, CEO of the Company.
Dr. Fields is a distinguished international expert in several areas of immunology, biochemistry, molecular biology, virology, and general microbiology. He has applied his knowledge to the study of viral hepatitis during an illustrious 32 year career at the Centers for Disease Control and Prevention publishing 160 manuscripts in international peer-reviewed journals and editing a book entitled "Artificial DNA". Dr. Fields pioneered research in using genetic engineering technology in the rational design of artificial antigens as targets for immunoassay development. He first joined CDC as an immunovirologist in 1976. During his thirty-two year career at the CDC, he was the Team Leader of the Assay Development and Cell Culture Team within the Division of Viral Hepatitis Center where he led the research on all hepatitis viruses including Hepatitis C Virus, and Hepatitis B Virus from 2002 until retiring recently.
"NanoViricides has developed a unique platform technology that is based on sound virological and biological principles. I am very pleased with the success of the nanoviricides drug candidates against numerous important viral diseases of public health significance. The novel host-cell-mimetic technology that Dr. Diwan invented has now culminated in the development of the Company's broad-spectrum antivirals. This technology represents an innovative and novel approach in the treatment of viral infections and I'm truly excited to be part of its future," said Dr. Fields.
At the CDC, in 1983, Dr. Fields was Chief, Molecular and Immunodiagnostic Section (MIDS), Hepatitis Branch, Division of Viral and Rickettsial Diseases. From 1990 to 1994, he was given the responsibility for the conduct of the WHO Collaborating Centre for Reference and Research on Viral Hepatitis at CDC with emphasis on technology transfer issues. Dr. Fields has been a consultant to various pharmaceutical industries including Bayer, Germany, Abbott Laboratories, Serologics, Inc., American Qualex, Eugene Tech International Inc., Nuclear Medical Laboratories, Dallas, TX, as well as Biokit, Barcelona, Spain, and Span Research Center, Surat, India. He is a member of the scientific advisory board of Cambridge Biotech, Galway, Ireland, and of NanoViricides, Inc.
About NanoViricides, Inc.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, Ebola virus, and dengue fever, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development efforts, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the “Management’s Discussion and Analysis” section of the Company’s Form 10-KSB and other reports and filings with the Securities and Exchange Commission.
For more information, please click here
Copyright © Business Wire 2008If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information